Embla Medical Hf S/Adr (OSSUY) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Embla Medical Hf.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:06.322 At this time, I would like to welcome everyone to this emblematical Q1 2025 00:00:06.322 -- 00:00:10.209 conference call. Today's call is being recorded. 00:00:10.209 -- 00:00:13.995 If you have any objections, please disconnect at this time. 00:00:13.995 -- 00:00:18.383 All participants will be on listen-only mode throughout the presentation, and afterwards 00:00:18.383 -- 00:00:21.048 there will be a question and answer session. 00:00:21.048 -- 00:00:24.093 I would now like to introduce CEO Sven Silversen. 00:00:24.093 -- 00:00:27.015 Sven, over to you. 00:00:27.605 -- 00:00:32.150 Thank you very much, and good morning, and welcome to the Ampla Medical conference call 00:00:32.150 -- 00:00:35.454 where we will review the first quarter for 2025. 00:00:35.454 -- 00:00:40.840 I'm Sveit Solvason, President and CEO of Ampla Medical, and joining me on today's 00:00:40.840 -- 00:00:45.145 call is our Chief Financial Officer, Artmar Svensdottir, and Ampla Medical's Head of 00:00:45.145 -- 00:00:50.511 Investor Relations, Klaus Sindahl. The presentation should take approximately 15 minutes, 00:00:50.511 -- 00:00:55.596 after which there will be an opportunity to ask questions during a Q&A session. 00:00:55.596 -- 00:00:58.638 If you now go to the next slide, please. 00:00:59.026 -- 00:01:04.332 We are off to a reasonably good start here in 2025. 00:01:04.332 -- 00:01:09.417 Sales in the first quarter amounted to 203 million, and organic growth came in 00:01:09.417 -- 00:01:11.259 at 4%, 00:01:11.259 -- 00:01:15.643 where we had a particularly good few weeks at the end of the quarter. 00:01:15.643 -- 00:01:20.949 Growth was strong in our prosthetics and neuro-orthotics segment, supported by, I 00:01:20.949 -- 00:01:26.174 would say, contin...